VRTX · News · 20260804N
Acquisition / Partnership / Divestiture
VERTEX PHARMACEUTICALS INC / MA · 2026-08-04 · Importance 71 · Surprise 60 · In source text
Vertex agreed to acquire Crinetics Pharmaceuticals for $85 per share in cash, representing approximately $10.0 billion of transaction value, or $8.8 billion net of estimated cash acquired. The acquisition is expected to close in the third quarter of 2026, subject to regulatory and Crinetics stockholder approvals. Vertex’s CEO highlighted two principal Crinetics assets that are projected to generate more than $5 billion in combined annual revenue. The transaction is intended to diversify Vertex’s therapeutic portfolio, particularly in endocrine and related disease areas.
Key facts
- Vertex announced a planned acquisition of Crinetics Pharmaceuticals for approximately $10.0 billion to further expand its therapeutic portfolio. source
- Crinetics agreed to be acquired by Vertex for $85.00 per share in cash, totaling approximately $10.0 billion. source
- Vertex's CEO said the two main assets acquired from Crinetics are projected to generate over $5 billion in combined annual revenue. source
- TD Cowen said Vertex anticipates closing the CRNX acquisition in Q3. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | positive | probable | — | Vertex's CEO said the two main assets acquired from Crinetics are projected to generate over $5 billion in combined annual revenue. |